GlassScriptPhysician profile
Gary Newsom
NPI 1992723019
$51,105.83
in general payments reported to CMS, 2019-2025
14 companies · $339 in 2025
The $339 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15K · 2020: $7,798 · 2021: $5,876 · 2022: $16K · 2023: $5,773 · 2024: $411 · 2025: $339.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $5,500 · Food and Beverage: $1,023.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $5,500.00 |
| Food and Beverage | $1,022.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $26,771.47 | 2021-2024 | |
| Allergan, INC. | $22,943.89 | 2019-2020 | |
| Alkermes, INC. | $259.43 | 2019-2024 | Aristada, Lybalvi |
| Janssen Pharmaceuticals, INC | $259.41 | 2023-2025 | Invega Sustenna, Invega Trinza |
| Otsuka America Pharmaceutical, INC. | $247.54 | 2019-2025 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $185.39 | 2021-2023 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $161.86 | 2022-2025 | Uzedy |
| Lundbeck LLC | $144.42 | 2023-2025 | Abilify Maintena |
| Almatica Pharma LLC | $43.09 | 2022 | |
| Bioxcel Therapeutics, INC. | $22.88 | 2023 | Igalmi |
| Alfasigma USA, INC. | $21.24 | 2022 | |
| Neurocrine Biosciences, INC. | $18.09 | 2024 | Ingrezza |
| Axsome Therapeutics, INC. | $14.61 | 2023 | Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $12.51 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Newsom listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.